A5046379913- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Complementary and Alternative Medicine Studies
- Hemodynamic Monitoring and Therapy
- Preterm Birth and Chorioamnionitis
- Pregnancy-related medical research
- Medical History and Research
- Assisted Reproductive Technology and Twin Pregnancy
- Cancer Genomics and Diagnostics
- Medical and Health Sciences Research
- BRCA gene mutations in cancer
- Health and Medical Studies
- Pregnancy and preeclampsia studies
- Biomedical and Chemical Research
- Radiomics and Machine Learning in Medical Imaging
- Body Image and Dysmorphia Studies
- Pericarditis and Cardiac Tamponade
- Nutrition, Genetics, and Disease
- Endometrial and Cervical Cancer Treatments
- Breast Lesions and Carcinomas
- Trauma, Hemostasis, Coagulopathy, Resuscitation
Helios Hospital Schwerin
2015-2022
MSH Medical School Hamburg – University of Applied Sciences and Medical University
2021
Helios Kliniken
2020
Die Johanniter
2010-2019
Comprehensive Cancer Center Erlangen
2016
Universitätsklinikum Erlangen
2016
Friedrich-Alexander-Universität Erlangen-Nürnberg
2016
Johanniter-Krankenhaus Bonn
2007-2016
Hochschule Hannover
2011
Federal Highway and Transport Research Institute
2011
FIFTH PART: APHASIA, AMUSIA AND AKALKULIA Henschen relates that on Feb. 28, 1912, the date of his sixty-fifth birthday, he was obliged by statute age limitation to retire as director medical clinic Stockholm, and thereby from usual clinical laboratory activities. This outlook not promising for original work in brain research, future investigations depended a review personal, anatomic material subject literature. However, undismayed after different publications disease heart (1913), auditory...
Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ER+ breast cancer, but it has administration and pharmacokinetic limitations. Pharmacodynamic data suggest complete ER degradation not achieved at fulvestrant's feasible dose. This presurgical study (NCT03236974) compared pharmacodynamic effects of fulvestrant AZD9496, a novel, orally bioavailable, nonsteroidal, potent SERD, treatment-naïve HER2- primary cancer awaiting...
JCO
<b>Introduction:</b> The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional for the assessment routine care women with invasive letrozole. parameters inclusion are presented discussed here. <b>Material Methods:</b> Between January 2008 December 2009 total 5045 310 centers were recruited to study. Inclusion criteria adjuvant treatment or...
Summary The validity and reliability of plasma volume estimation using indocyanine green were investigated in five vitro experiments three vivo series. measurements reflected real volumes with an error about 1%. Comparative the same patients or Cr 51 labelled red cells differed by 1.7% (r = 0.97). mean (SD) difference between two successive was 38 (43) ml 0.99). Plasma measured before 7 min after a hyperosmolar saline bolus (100 ml, 1 molar) increased 223 (102) 286 (49) when determined...
<b><i>Background:</i></b> Decision-making for or against neoadjuvant adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some may unnecessarily undergo be exposed to the associated toxicity. The aim of this study was identify patient population whom issue bear relevance. <b><i>Methods:</i></b> Patients being treated letrozole prospective multicenter...
Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim this study was to analyze persistence palliative aromatase inhibitor (AI) monotherapy in MBC patients. EvAluate-TM is a prospective, multicenter, noninterventional evaluate with letrozole postmenopausal women receptor–positive cancer. To assess persistence, defined as the time from start end (TTEOT), two pre-specified...
The classic mid-trimester preterm premature rupture of membranes (PPROM) is defined as a the fetal prior to 28 weeks gestation (WG) with oligo/anhydramnion; it complicates approximately 0.4-0.7% all pregnancies and associated very high neonatal mortality morbidity. Antibiotics have limited success prevent bacterial growth, chorioamnionitis inflammation. repetitive amnioinfusion does not work because fluid lost immediately after intervention. continuous through transabdominal port system or...
6 Background: Adjacent ductal carcinoma in situ (DCIS) is found approximately 45% of invasive carcinomas (IDC) the breast. Pure DCIS overexpresses HER2 45%. There uncertainty whether adjacent impacts on response to neoadjuvant chemotherapy and trastuzumab as well expression IDC component or changes throughout treatment. Methods: Core biopsies surgical tissue from participants GeparQuattro study with HER2-positive were centrally examined for area before after receiving...